BIO 2020 Notebook: McMurry-Heath On Restoring Hope, Greenwood On Defeating Climate Skeptics
Executive Summary
News and views from day one of BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change.
You may also be interested in...
BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
Regeneron Maintains Its Momentum During Pandemic
The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.
Pink Sheet Podcast: US FDA Adcomm Open Public Hearings, Clinical Trial Diversity Plans, Stealth’s Elamipretide
Pink Sheet reporter and editors discuss Richard Pazdur’s call for more diverse opinions in FDA advisory committee meeting open public hearings, agency questions about the stakeholders sponsors consult to execute clinical trial diversity plans, and the pending review of Stealth BioTherapeutics’ application for the Barth Syndrome candidate elamipretide.